Leerink Raises Price Target on BeOne Medicines Following FDA Approval of Sonrotoclax
On May 15, 2026, Leerink raised its price target for BeOne Medicines (NASDAQ:ONC) to $367 from $364 while maintaining an Outperform rating. This follows the U.S. FDA granting accelerated approval on May 13, 2026, of sonrotoclax (Beqalzi), a next-generation BCL2 inhibitor for relapsed or refractory mantle cell lymphoma.
Tickers: $ONC
Topics: FDA Approval Pharmaceuticals Stock Rating